World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT03451812
Date of registration: 26/02/2018
Prospective Registration: No
Primary sponsor: Chang Gung Memorial Hospital
Public title: Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer PCAPETMR
Scientific title: Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer
Date of first enrolment: January 1, 2017
Target sample size: 120
Recruitment status: Recruiting
URL:  https://clinicaltrials.gov/show/NCT03451812
Study type:  Observational
Study design:   
Phase: 
Countries of recruitment
Taiwan
Contacts
Name:     Gigin Lin, MD, PhD
Address: 
Telephone: 886-3281200
Email: giginlin@cgmh.org.tw
Affiliation: 
Name:     Gigin Lin, MD, PhD
Address: 
Telephone: 886-3281200
Email: giginlin@cgmh.org.tw
Affiliation: 
Name:     Gigin Lin, MD, PhD
Address: 
Telephone:
Email:
Affiliation:  Medical Imaging and Intervention, Chang Gung Memorial Hospital
Key inclusion & exclusion criteria

Inclusion Criteria:

- Males

- 40-85 years of age

- Patients with a biopsy-proven or clinically highly suspected prostate adenocarcinoma,
or benign prostatic hyperplasia

- Able to tolerate [11C]Choline PET scan and MRI scan

- Written informed consent from the patient

Exclusion Criteria:

- Acute prostatitis or non-urologic bacterial infection requiring medical treatment
within the last 3 months.

- History of AIDS in the period prior to the screening.3

- Contraindications to [11C]Choline PET/MR scans

1. Surgical implants including pacemaker implants, cochlear implants, dentures held
in place by magnets imbedded in the gums and aneurysm clips except those inserted
at CGMH

2. Metallic prosthesis of the hip or pelvic region

3. Renal function impairment with estimated glomerular filtration rate (eGFR) < 30
ml/min/1.73 m2

4. Claustrophobia

5. Medical drugs with choline

6. Previous allergy to carbon-labeled radionuclide

- Active other malignancy within the last 2 years

- Subject which in the opinion of the investigator preclude participation for scientific
reasons, for reasons of compliance, or for reasons of the subject's safety.

- Prisoners or patients with mental illness



Age minimum: 40 Years
Age maximum: 85 Years
Gender: Male
Health Condition(s) or Problem(s) studied
Prostate Adenocarcinoma
Intervention(s)
Primary Outcome(s)
Diagnostic Accuracy [Time Frame: 1 year]
Secondary Outcome(s)
Secondary ID(s)
104-4855A
105-6435C
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history